Several other research firms also recently issued reports on GRCL. Stifel Nicolaus assumed coverage on Gracell Biotechnologies in a report on Thursday, October 19th. They set a buy rating and a $11.00 price objective on the stock. Citigroup cut their target price on Gracell Biotechnologies from $12.00 to $11.00 and set a buy rating on the stock in a research note on Tuesday, August 29th. Finally, HC Wainwright boosted their price objective on Gracell Biotechnologies from $12.00 to $13.00 and gave the stock a buy rating in a research note on Monday, August 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of Buy and an average target price of $13.67.
Gracell Biotechnologies Stock Performance
Institutional Investors Weigh In On Gracell Biotechnologies
Large investors have recently modified their holdings of the stock. Brainard Capital Management LLC bought a new position in Gracell Biotechnologies in the 1st quarter valued at $48,000. Wells Fargo & Company MN lifted its stake in shares of Gracell Biotechnologies by 125.7% in the 2nd quarter. Wells Fargo & Company MN now owns 10,209 shares of the company’s stock valued at $39,000 after purchasing an additional 5,685 shares during the period. Jane Street Group LLC acquired a new stake in Gracell Biotechnologies during the 1st quarter worth $31,000. Tower Research Capital LLC TRC raised its stake in Gracell Biotechnologies by 1,279.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 8,357 shares of the company’s stock worth $27,000 after buying an additional 7,751 shares during the period. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Gracell Biotechnologies during the 3rd quarter worth $2,448,000.
About Gracell Biotechnologies
Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.
- Five stocks we like better than Gracell Biotechnologies
- How to Invest and Trade Chinese Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 11/13 – 11/17
- What Are Dividends? Buy the Best Dividend Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Gracell Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gracell Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.